Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Abstract Background To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs. Methods Patients in SELECT-NEXT, a randomised controlled trial, were on a background of csDMARDs and received upadacitinib 15 mg and 30 mg or...

Full description

Bibliographic Details
Main Authors: Vibeke Strand, Janet Pope, Namita Tundia, Alan Friedman, Heidi S. Camp, Aileen Pangan, Arijit Ganguli, Mahesh Fuldeore, Debbie Goldschmidt, Michael Schiff
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Patient-reported outcomes
JAK inhibitor
Health-related quality of life
Treatment outcomes
Online Access:https://doi.org/10.1186/s13075-019-2037-1

Internet

https://doi.org/10.1186/s13075-019-2037-1

Similar Items